ReviewEuropean journal of pharmacology2019
Selected nucleos(t)ide-based prescribed drugs and their multi-target activity.
Review in European journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- TargetingFrontiers in microbiology · 2026Review
- Potential Benefits of In Silico Methods: A Promising Alternative in Natural Compound's Drug Discovery and Repurposing for HBV Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Immobilized Nucleoside 2'-Deoxyribosyltransferases from Extremophiles for Nucleoside Biocatalysis.ACS omega · 2025Article
- Guanine derivatives as promising candidates for the development of purine-based antimalarial drugs.Frontiers in parasitology · 2025Article
- Nucleoside Analogues for Chagas Disease and Leishmaniasis Therapy: Current Status and Future Perspectives.Molecules (Basel, Switzerland) · 2024Review
- Nanotechnology Lighting the Way for Gene Therapy in Ophthalmopathy: From Opportunities toward Applications.Molecules (Basel, Switzerland) · 2023Review
- Hepatitis B Therapeutic Vaccine: A Patent Review.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The First 5'-Phosphorylated 1,2,3-Triazolyl Nucleoside Analogues with Uracil and Quinazoline-2,4-Dione Moieties: A Synthesis and Antiviral Evaluation.Molecules (Basel, Switzerland) · 2022Article
- Antiviral nucleoside analogs.Chemistry of heterocyclic compounds · 2021Article
- An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms.Turkish journal of biology = Turk biyoloji dergisi · 2021Review
- Development of a SimpleAntimicrobial agents and chemotherapy · 2020Article
- An efficient synthesis tetrazole and oxadiazole analogues of novel 2'-deoxy-C-nucleosides and their antitumor activity.Bioorganic & medicinal chemistry letters · 2020Article
- One drug to treat many diseases: unlocking the economic trap of rare diseases.Metabolic brain disease · 2020Review
- COVID-19 therapy: What weapons do we bring into battle?Bioorganic & medicinal chemistry · 2020Article
- Intramolecular Michael Additions in Uridine Derivatives: Isolation of the Labile 5'O-C6 Cyclonucleoside.ACS omega · 2020Article
- Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens.Antiviral chemistry & chemotherapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleos(t)ide analogues play pivotal roles as antiviral, cytotoxic or immunosuppressive agents. Here, we review recent reports of nucleoside analogues that exhibit broad-spectrum activity towards multiple life-threatening RNA and DNA viruses. We also present a discussion about nucleoside antimetabolites-approved antineoplastic agents-that have recently been shown to have antiviral and/or antibacterial activity. The approved drugs and drug combinations, as well as recently identified candidates for investigation and/or experimentation, are discussed. Several examples of repurposed drugs that have already been approved for use are presented. This strategy can be crucial for the first-line treatment of acute infections or coinfections and for the management of drug-resistant strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.